Agios Exec Andrew Hirsch Jumps to C4 Therapeutics for CEO Role

Andrews Hirsch has joined C4 Therapeutics as its new CEO. He comes to the Watertown, MA-based biopharmaceuticals company from Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]), where he was chief financial officer and head of corporate development. Marc Cohen, the co-founder and interim CEO of C4, will remain executive chairman of the company. C4 is developing drugs that harness a cellular mechanism for disposing of unwanted proteins as a way of treating disease. Hirsch’s hire comes three months after C4 closed a $170 million Series B round of funding as it looks ahead to human testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.